MedPath

Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma

Phase 2
Completed
Conditions
Clear Cell Renal Cell Carcinoma
Interventions
Registration Number
NCT03680521
Lead Sponsor
Mirati Therapeutics Inc.
Brief Summary

The study will evaluate the clinical activity of sitravatinib in combination with nivolumab in patients with locally-advanced clear cell renal cell carcinoma (ccRCC) in the neoadjuvant setting prior to nephrectomy.

Detailed Description

Sitravatinib is a receptor tyrosine kinase inhibitor (TKI) that targets multiple closely related receptor tyrosine kinase pathways including VEGFR, PDGFR, c-KIT, MET, and the TAM family of receptors (TYRO3, AXL, and MER). Nivolumab is a monoclonal antibody directed against PD-1 and blocks the interaction between PD-1 and its ligands, thereby releasing PD-1-mediated inhibition of T-cell proliferation (including cytotoxic CD8+ T-cells) and cytokine production. Together, sitravatinib and nivolumab may cooperate to elicit greater anti-tumor activity than either agent alone, as sitravatinib is predicted to enhance several steps in the cancer immunity cycle that may augment the efficacy of nivolumab.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
25
Inclusion Criteria
  1. Imaging results consistent with locally-advanced RCC
  2. Candidate for partial or complete nephrectomy as part of treatment plan.
  3. Measurable disease per RECIST version 1.1.
  4. ECOG performance status 0 or 1.
  5. Adequate bone marrow and organ function.
Read More
Exclusion Criteria
  1. Prior systemic anti-tumor treatment for RCC.
  2. Patients who are receiving any other investigational agents.
  3. Clinical status indicating that immediate surgery (within 6 weeks) is warranted regardless of whether neoadjuvant therapy is to be administered, as assessed by the treating surgeon.
  4. Inability to undergo baseline tumor biopsy.
  5. Active or prior documented autoimmune or immunocompromising conditions.
  6. Uncontrolled hypertension.
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Sitravatinib and nivolumabSitravatinibSitravatinib oral capsule administered daily 2 weeks alone then in combination with nivolumab administered as 240 mg IV every 2 weeks. Total treatment duration: 6-8 weeks prior to planned nephrectomy.
Sitravatinib and nivolumabNivolumabSitravatinib oral capsule administered daily 2 weeks alone then in combination with nivolumab administered as 240 mg IV every 2 weeks. Total treatment duration: 6-8 weeks prior to planned nephrectomy.
Primary Outcome Measures
NameTimeMethod
Point in Time Objective Response Prior to SurgeryBaseline to date of surgery (maximum time to surgery was approximately 13 weeks)

Number and percentage of participants who experienced a response prior to surgery in accordance with RECIST 1.1.

* CR is defined as complete disappearance of all baseline target and non-target lesions with the exception of nodal disease;

* PR is defined as \>=30% decrease under baseline of the sum of diameters of all target measurable lesions;

* Stable Disease (SD) is concluded when the single point in time response does not qualify for CR, PR or Progressive Disease (PD);

* PD is defined as a 20% increase in the sum of diameters of target measurable lesions above the smallest sum observed with a minimum absolute increase of 5 mm, or unequivocal progression of pre-existing nontarget lesions.

Percentage of Participants Who Achieved a Point in Time Objective Response (Either Complete or Partial Response [CR or PR]) Prior to SurgeryBaseline to date of surgery (maximum time to surgery was approximately 13 weeks)

Objective response is defined as the percent of participants documented by investigator assessment to have Complete Response (CR) or Partial Response (PR) in accordance with the Response Evaluation Criteria in Solid Tumors (RECIST 1.1). CR is defined as complete disappearance of all baseline target and non-target lesions with the exception of nodal disease; PR is defined as \>=30% decrease under baseline of the sum of diameters of all target measurable lesions.

Secondary Outcome Measures
NameTimeMethod
Disease Free Survival (DFS)Up to 3 years after surgery (maximum time to surgery was approximately 13 weeks)

DFS was defined as the time from date of surgery to disease recurrence or death whichever occurred first.

Change From Baseline in CD4+ T-cells in the TumorBaseline to date of surgery (maximum time to surgery was approximately 13 weeks)

Tumor tissue was collected from study biopsies and surgical samples, and was used to assess mean CD4+ T-cells using immunohistochemistry.

Number of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs)Day 1 until 28 days after last dose of study drug or surgery, whichever occurred last (up to a maximum of 13 weeks)

TEAEs occured after the first dose of any study treatment or any preexisting condition that increased in severity after the first dose of study treatment and prior to 28 days after last dose of study drug or surgery, whichever occurred last.

TEAEs were graded using Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

Time to SurgeryDay 1 up to date of surgery (maximum time to surgery was approximately 13 weeks)

Time to surgery was defined as the number of calendar days between Day 1 and the planned nephrectomy.

Change From Baseline in CD8+ T-cells in the TumorBaseline to date of surgery (maximum time to surgery was approximately 13 weeks)

Tumor tissue was collected from study biopsies and surgical samples, and was used to assess mean CD8+ T-cells using immunohistochemistry.

Blood Plasma Concentrations of SitravatinibDay 1 (pre-dose, and 30 minutes and 4 hours post-dose), Day 15 (pre-dose) and Day 43 (pre-dose)

The blood plasma concentrations of sitravatinib were determined using blood samples. Blood samples for analysis of blood plasma concentrations of sitravatinib were taken after scheduled vital signs and triplicate electrocardiogram assessments.

Percentage Change From Baseline in Programmed Death Ligand 1 (PD-L1) Expression in the TumorBaseline to date of surgery (maximum time to surgery was approximately 13 weeks)

Tumor tissue was collected from study biopsies and surgical samples. Tumor tissue was used to assess the mean PD-L1 expression in the tumor via immunohistochemistry and/or immunofluorescence.

Change From Baseline in Regulatory T-cells (Tregs) in the TumorBaseline to date of surgery (maximum time to surgery was approximately 13 weeks)

Tumor tissue was collected from study biopsies and surgical samples, and was used to assess mean Tregs using immunohistochemistry.

Change From Baseline of Selected Cytokines in Peripheral BloodBaseline to Day 43

Cytokines measured in peripheral blood were soluble CD27 (sCD27), eotaxin, macrophage inflammatory protein 1b (MIP-1b), and soluble programmed cell death protein 1 (sPD-1).

Change From Baseline in Myeloid-derived Suppressor Cells (MDSCs) in the TumorBaseline to date of surgery (maximum time to surgery was approximately 13 weeks)

Tumor tissue was collected from study biopsies and surgical samples, and was used to assess mean MDSCs using immunohistochemistry.

Change From Baseline in Ratio of Type 1 to Type 2 Tumor Associated Macrophages in the TumorBaseline to date of surgery (maximum time to surgery was approximately 13 weeks)

Tumor tissue was collected from study biopsies and surgical samples, and was used to assess mean ratio of Type 1 to Type 2 tumor associated macrophages using immunohistochemistry.

Trial Locations

Locations (1)

MD Anderson Cancer Center

🇺🇸

Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath